1,000
Participants
Start Date
April 1, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
July 31, 2026
In-vitro urinary diagnostic test
Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
European Kidney Health Aliance, Brussels
Department of Internal Medicine, Division of Hypertension, University Medical Centre Ljubljana, Ljubljana
Hypertension in Africa Research Team, Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom
Alliance for the Promotion of Preventive Medicine, Mechelen
Steno Diabetes Center Copenhagen, Gentofte Municipality
Diabetes Liga, Ghent
Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo
Mosaiques-Diagnoostics and Therapeutics AG, Hanover
Biomedical Research Foundation of the Academy of Athens, Athens
Department of Internal Medicine, Faculty of Clinical Sciences, College of Health Sciences, University of Abuja, Abuja
Department of Hypertension, Medical University of Gdańsk, Gdansk
First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow
Alliance for the Promotion of Preventive Medicine
UNKNOWN
KU Leuven
OTHER